Nora Möhn

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy

Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events

Added value of optic nerve lesions for multiple sclerosis diagnostic criteria

Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy

Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset

Combined treatment with allogeneic Epstein–Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report

Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy

Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome

18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients

Interleukin 17, Produced by γδ T Cells, Contributes to Hepatic Inflammation in a Mouse Model of Biliary Atresia and Is Increased in Livers of Patients